2022
Development and pilot-testing of a hepatitis C reinfection prevention intervention for patients in treatment for hepatitis C infection
Viera A, Grau L, Fisher J, Farnum S, Tetrault J, Scott G, Heimer R. Development and pilot-testing of a hepatitis C reinfection prevention intervention for patients in treatment for hepatitis C infection. Drug And Alcohol Dependence Reports 2022, 3: 100038. PMID: 36845980, PMCID: PMC9948939, DOI: 10.1016/j.dadr.2022.100038.Peer-Reviewed Original Research
2020
Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention
Severe B, Tetrault JM, Madden L, Heimer R. Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention. Drug And Alcohol Dependence 2020, 213: 108116. PMID: 32599493, DOI: 10.1016/j.drugalcdep.2020.108116.Peer-Reviewed Original ResearchOpioid treatment programsOpioid use disorderOpioid agonist treatmentHCV treatmentOUD treatmentTreatment retentionHepatitis C virus infection treatmentControl groupSurvival analysisHepatitis C virus infectionTreatment programHCV care continuumC virus infectionChronic HCV infectionOutcomes of interestHCV infectionAgonist treatmentPatient retentionCare continuumVirus infectionTreatment groupsUse disordersPatientsBaseline covariatesInfection treatment
2017
Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program
Butner JL, Gupta N, Fabian C, Henry S, Shi JM, Tetrault JM. Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. Journal Of Substance Use And Addiction Treatment 2017, 75: 49-53. PMID: 28237054, DOI: 10.1016/j.jsat.2016.12.014.Peer-Reviewed Original ResearchConceptsDirect acting antiviralsOpioid treatment programsPercent of patientsHCV treatmentHCV infectionActing antiviralsTreatment outcomesTreatment programOral HCV treatmentSustained virologic responseHCV treatment outcomesRoutine clinical careOngoing drug useVirologic responseRetrospective studyClinical careGeneral populationPatientsDrug useTreatmentOutcomesAntiviralsInfectionPercentPWID